Modular Phase 1B Hypothesis-Testing, Biomarker-Driven, Talazoparib Combination Trial (TalaCom)
This study is testing new combinations of cancer medicines to see how well they work against solid tumors that have spread. By using these treatments together, researchers hope to better block cancer cells from repairing themselves and growing.
This trial is for adults with advanced solid tumors that have specific genetic changes or markers. You must be in generally good health and have not had recent major surgeries or specific types of cancer treatment.
Participants will receive a combination of talazoparib and one of the other study drugs to determine the safest and most effective dose. You will be closely monitored by the medical team to see how your body responds to the treatment and to track any side effects.
The study is currently open for recruitment and is located in Houston, Texas.
- 1Researchers are testing drug combinations to stop cancer cell growth.
- 2The trial focuses on tumors with specific genetic changes.
- 3Your health and safety will be monitored closely throughout the study.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.